Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone

Jannuzzo, M. G.; Salle, E. Di; Spinelli, R.; Pirotta, Nicoletta; Buchan, Peter; Bello, Akintunde

doi:10.1007/s10549-008-9949-9

Cited by 26 publications

(9 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…our experience SOFT and TEXT have been designed with triptorelin 3.75 mg, in line with previous evidence [20]. However, also the 11.25 mg formulation can be a feasible option.…”

supporting

confidence: 69%

Are we Ready to Change Clinical Practice after the ‘Soft and Text’ Results?

2015

View full text Add to dashboard Cite

Keywords• aromatase inhibitors • breast cancer • exemestane • triptorelin Luminal breast cancer is the most common subtype among molecular subgroups of breast cancer identified by gene profiling, and it accounts for more than half of all breast cancer cases around the world [1].These cancers are characterized by hormonal receptors and low proliferative activity; in particular luminal A (high rate of estrogen and progesterone receptors, low proliferative index, low grading) is the breast cancer type with the best prognosis, while luminal B can be further subclassified into two phenotypes, depending on the expression of HER2 (luminal B HER2 positive or luminal B HER2 negative). Luminal B is characterized by low rate of estrogen and progesterone receptors and high proliferative index [2].The breast cancer incidence has increased in the last years, especially among younger women [3]. The treatment of premenopausal women involves all the problems correlated to fertility preservation, an important issue for every woman affected by cancer [3,4].The gold standard treatment for premenopausal women with hormone receptors positive early breast cancer is tamoxifen for 5 years, with or without ovarian suppression, which has demonstrated a significant effect on overall survival (OS) and in the reduction of relapses [5].However, the association of ovarian suppression with aromatase inhibitors has emerged as a valid alternative in the adjuvant setting for premenopausal patients. The Phase III SOFT and TEXT trials conducted by the International Breast Cancer Study Group (IBCSG) in collaboration with the Breast International Group (BIG) and the North American Breast Cancer Group (NABCG), involved 4690 patients in 27 countries across six continents [6]. These researchers demonstrated, for the first time, the superiority of exemestane in combination with the gonadotropin-releasing hormone analogue (GnRH-A) triptorelin, over tamoxifen plus ovarian suppression in the prevention of recurrence in young premenopausal women with hormone-sensitive early-stage breast cancer [6].Exemestane and triptorelin treatment determined a decrease of 28% in the relative risk of developing a recurrence, with a disease-free survival (DFS) at 5 years of 91.1%, compared with 87.3% in the tamoxifen group [6]. Despite the significant improvement in DFS, an improvement in OS has not been demonstrated in

show abstract

“…our experience SOFT and TEXT have been designed with triptorelin 3.75 mg, in line with previous evidence [20]. However, also the 11.25 mg formulation can be a feasible option.…”

supporting

confidence: 69%

Are we Ready to Change Clinical Practice after the ‘Soft and Text’ Results?

2015

View full text Add to dashboard Cite

show abstract

“…L'association inhibiteur de l'aromatase et analogue à la LH-RH entraîne une déplession estrogénique plus marquée que les analogues seuls [41]. Les études cliniques chez la femme dans ménopausées sont en cours.…”

Section: Les Inhibiteurs De L'aromataseunclassified

Hormonothérapie du cancer du sein

Delozier¹

2010

Journal de Gynécologie Obstétrique et Biologie de la Reproducti

View full text Add to dashboard Cite

“…In women with established breast cancer cotreatment of GnRH-agonist with tamoxifene and aromatase inhibitors elicits additional therapeutic effects regarding an event free survival and overall survival [15][16][17].…”

Section: Oncological Aspects Of Gnrh-agonists and Other Medicationsmentioning

confidence: 99%

The value of gonadotropin-releasing hormone-agonists together with other drugs for medical treatment and prevention

Schindler¹

2009

Gynecological Endocrinology

View full text Add to dashboard Cite

show abstract

Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone

Abstract: Coadministration of T and EX resulted in greater estrogen suppression than when T was given alone. These findings could translate into improved clinical outcomes for premenopausal breast cancer patients receiving LHRH agonists.

Cited by 26 publications

References 20 publications

Are we Ready to Change Clinical Practice after the ‘Soft and Text’ Results?

Are we Ready to Change Clinical Practice after the ‘Soft and Text’ Results?

Hormonothérapie du cancer du sein

The value of gonadotropin-releasing hormone-agonists together with other drugs for medical treatment and prevention

Contact Info

Product

Resources

About